secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274094
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine Q3 net loss $14.1M; bitopertin Phase 2 enrollment complete
------------------------------------------------------------------------

- Cash $370.5M as of Sep 30, 2023; expected to fund operations into 2026.
- Completed enrollment for BEACON (open-label) and AURORA (placebo-controlled) Phase 2 trials of bitopertin in EPP/XLP.
- Updated BEACON data including pivotal endpoint (cumulative time in sunlight) to be presented at ASH 2023.
- Initiated Phase 1 trial of DISC-3405 for PV; received FDA fast track designation.
- R&D expenses $14.4M (up from $7.9M YoY) driven by portfolio progression and headcount.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523274094/0001193125-23-274094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523274094/d594333d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer